(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The most effective method to Make a Dazzling Site in 5 Basic Advances - 2Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026
- 3Extremely Rare Snub-Nosed Monkey Was Just Born for the First Time Outside of Asia
- 4Venus shines at its best in spring and summer 2026 — here's what to look for
- 5German hauliers warn soaring energy prices may soon impact consumers
- What to know about the "wild, wild West" of viral peptide claims
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
- Sexual violence is being used as a weapon in Sudan's war, doctors group says
- Vote In favor of Your Favored Kind Of Bites
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
- Most loved Well known Accessory Styles For 2024
- Russia earning billions from Hormuz blockade, German trade body says
